Jean Bennett

CIK: 0001872219

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RGNX

REGENXBIO Inc.

Director

IRD

Opus Genetics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

RGNX
REGENXBIO Inc.
May 29, 2026
Award(A)
Direct
9.8K shares-
IRD
Opus Genetics, Inc.
Apr 20, 2026
Award(A)
Direct
24.4K shares-
IRD
Opus Genetics, Inc.
Jan 1, 2026
Award(A)
Direct
21.1K shares-
RGNX
REGENXBIO Inc.
May 30, 2025
Award(A)
Direct
7.8K shares-
IRD
Opus Genetics, Inc.
Apr 30, 2025
Award(A)
Direct
79.5K shares-
IRD
Opus Genetics, Inc.
Jan 2, 2025
Award(A)
Direct
34K shares-
IRD
Opus Genetics, Inc.
Oct 22, 2024
Award(A)
Direct
100K shares-

		Type	Shares	Price		Ownership
May 29, 2026	RGNX REGENXBIO Inc.	Award(A)	9,807	-	$0	Direct
Apr 20, 2026	IRD Opus Genetics, Inc.	Award(A)	24,367	-	$0	Direct
Jan 1, 2026	IRD Opus Genetics, Inc.	Award(A)	21,127	-	$0	Direct
May 30, 2025	RGNX REGENXBIO Inc.	Award(A)	7,768	-	-	Direct
Apr 30, 2025	IRD Opus Genetics, Inc.	Award(A)	79,504	-	-	Direct
Jan 2, 2025	IRD Opus Genetics, Inc.	Award(A)	34,021	-	$0	Direct
Oct 22, 2024	IRD Opus Genetics, Inc.	Award(A)	100,000	-	$0	Direct

1-7 of 7 transactions

About Bennett Jean

Bennett Jean (SEC CIK 0001872219) files insider reports with the SEC as Director of REGENXBIO Inc. (RGNX) and Director of Opus Genetics, Inc. (IRD).

Signal8 holds 8 ownership filings by Bennett Jean (1 Form 3, 7 Form 4), filed between Oct 24, 2024 and Jun 2, 2026. Those filings report 7 transactions, from Oct 22, 2024 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bennett Jean's filings is in ROCKVILLE, MD.

Recent filings by Bennett Jean

May 29, 2026: Grant or award of RGNX shares (Form 4, code A).
Apr 20, 2026: Grant or award of IRD shares (Form 4, code A).
Jan 1, 2026: Grant or award of IRD shares (Form 4, code A).
May 30, 2025: Grant or award of RGNX shares (Form 4, code A).
Apr 30, 2025: Grant or award of IRD shares (Form 4, code A).

Other insiders filing for REGENXBIO Inc. (RGNX)

Malzahn Craig, Chief Technology Officer
Christmas Patrick J., Chief Strategy & Legal Officer
PAKOLA STEVE, Chief Medical Officer
Chan Mitchell, Chief Financial Officer
Ciongoli Gregory Austin, Director
Simpson Curran, Chief Executive Officer

How to read Form 4 transaction codes